Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Corcept Therapeutics (CORT)

Corcept Therapeutics (CORT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Corcept Therapeutics 101 REDWOOD SHORES PARKWAY REDWOOD CITY CA 94065 USA

www.corcept.com Employees: 730 P: 650-327-3270

Sector:

Medical

Description:

Corcept is focused on the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncology disorders which are associated with the activity of the hormone cortisol, also known as the stress hormone. Corcept's only marketed drug, Korlym (mifepristone), is approved for the once-daily oral treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, suffering from type II diabetes or glucose intolerance and who have failed surgery or are not suitable for surgery.

Key Statistics

Overview:

Market Capitalization, $K 4,304,956
Enterprise Value, $K 4,184,456
Shares Outstanding, K 106,374
Float, K 84,248
% Float 79.20%
Short Interest, K 12,466
Short Float 11.72%
Days to Cover 4.78
Short Volume Ratio 0.57
% of Insider Shareholders 20.80%
% of Institutional Shareholders 93.61%

Financials:

Annual Sales, $ 761,410 K
Annual Net Income, $ 99,650 K
Last Quarter Sales, $ 202,130 K
Last Quarter Net Income, $ 24,290 K
EBIT, $ 44,810 K
EBITDA, $ 41,600 K

Growth:

1-Year Return -32.53%
3-Year Return 77.89%
5-Year Return 57.72%
5-Year Revenue Growth 115.17%
5-Year Earnings Growth -3.53%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings 0.20 on 02/24/26
Next Earnings Date 05/04/26
Earnings Per Share ttm 0.82
EPS Growth vs. Prev Qtr 25.00%
EPS Growth vs. Prev Year -23.08%
Annual Dividend & Yield (Paid) 0.00 (0.00%)
Annual Dividend & Yield (Fwd) 0.00 (0.00%)
Dividend Payout Ratio 0.00%

CORT Ratios

Ratio
Price/Earnings ttm 41.24
Price/Earnings forward 143.91
Price/Earnings to Growth N/A
Return-on-Equity % 15.19%
Return-on-Assets % 11.93%
Profit Margin % 13.09%
Debt/Equity 0.00
Price/Sales 4.72
Price/Cash Flow 37.46
Price/Book 5.49
Book Value/Share 6.16
Interest Coverage -1.15
60-Month Beta 0.29
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.